Hansen Medical iss doch schei

::::::::: 1,99 $ +1,02% +0,02 $ In Euro: 1,4422 € | Nasdaq ,GrB

RTK 1,99  $ RTP +1,02%  EK 1,97 $ last 100 full 330.759 peak 2,05 buran

Preis 2,00 $ Schleife 2.800 spread 1,01%

buran & Hansen ..and good luck

Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 1,96 2,05 1,9599  2,00 $ 351.259 0,70 M

GrB

Preis pro Schein 1,81 $ Schleife 400 spread 0,56%

buran und MfG und Dreimal Rosamunde

Zeit   Kurs Stück
  15:30:00§1,87 $ 1.026
_____________________
GRATULATION

:::::::::::::::::: 1,363 € +3,10% +0,041 € ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.11.13      1,87      1,88§1,77 1,86 $ 101.727 141 T

..ich das buran hör gerade nen interessanten Bericht im ISS Radio ..es geht um den neusten Fund der abhandenen Kunst Schätze ..also Gemälde und Bilder mit Taxe 1 Milliarde ..jener Wert wird enorm nach oben reviedieren durch den nun medialen Rummel in Gange kommt ..also Bilanz::: GELD

Kosmonova buran

..GRATULATION

RTP -2,67 EK 1,87 $ last shares 100 full RT 98.554 peak 1,87 ,GrB

and the physicians that treat and care for them, around the world.
www.hansenmedical.com/company/mission.php

To enable Cardiac Arrhythmia and Endovascular Procedures and to improve patient outcomes through the use of Intravascular Robotics
www.hansenmedical.com/company/mission.php

robotics, was born from the vision of creating a new generation of advanced medical robotics- a generation that would empower and protect physicians while providing enhanced care for patients. The Sensei® Robotic Catheter System and Artisan® Control Catheter used in electrophysiology procedures were the first realization of this vision. The Magellan™ Robotic System and Magellan™ Robotic Catheter are the next generation of intravascular robotics technology designed for peripheral vascular interventions. Hansen Medical headquarters are in Mountain View, California.

We believe that our new Magellan Robotic System has the potential to simplify and enhance catheter navigation and therapeutic interventions for peripheral vascular disease. The Magellan Robotic System, used in combination with the Magellan Robotic Catheter, will have the potential to enable physicians to cannulate target lesions through robotic control of the distal tips of sheath and leader catheters and through robotic control of guidewires.

We believe that our Sensei X Robotic Catheter System for electrophysiology procedures facilitate manipulation and stable control of catheter and catheter-based technologies during electrophysiology (EP) procedures. The System provides navigation of flexible catheters, resulting in stability, and control in interventional procedures. One key is our proprietary Instinctive Motion™ technology that accurately and responsively translates the physician’s hand movements at the motion controller to the robotically controlled steerable catheter in the patient’s anatomy.

At Hansen Medical, we are passionate about creating robotic solutions that provide physicians with a suite of tools for their procedural and therapeutic success. We believe that better tools will impact outcomes and patient care.
www.hansenmedical.com/company/profile.php

2012

   Magellan™ Robotic System FDA Clearance.

2011

   Magellan™ Robotic System CE Mark for peripheral vascular intervention.
   Partnership with Philips Healthcare on fiber optic shape sensing and localization technology.

2010

   First sale of Lynx® Irrigated Ablation Catheter in Europe
   First patients successfully treated with new flexible catheter vascular robotic system
   Hansen Medical Opens European Commercialization and Training Center
   Partnership with Philips Healthcare on the development of the vascular robotic system announced.

2009

   Sensei® X Robotic Catheter System FDA clearance & CE Mark
   Artisan Extend™ introduction in the U.S

2008

   CoHesion™ 3D Visualization Module FDA clearance & CE Mark

2007

   Sensei® Robotic Catheter System & Artisan® Control Catheter FDA clearance & CE Mark
   First Customer Shipment
   European Subsidiary opened in United Kingdom

2006

   IPO

2002

   Founded
www.hansenmedical.com/company/profile.php

nvestor Contacts:
Peter J. Mariani  
Chief Financial Officer  
Hansen Medical, Inc.  
650.404.5800     FTI Consulting, Inc.
Brian Ritchie
(212) 850-5683
Brian.Ritchie@fticonsulting.com

John Capodanno
212.850.5705
John.Capodanno@fticonsulting.com

88 Pine Street, 32nd Floor
New York, NY 10005

@Kosmonova buran,ISS
www.hansenmedical.com/investor-relations/...ct-information.php

Event Details
     Title§Hansen Medical Inc at Barclays Select Growth Conference
Date and Time Monday, November 18, 2013 9:05 a.m. ET  
  Location§New York City, NY  US
www.hansenmedical.com/investor-relations/...-recent-events.php

  08/16/13         3§Initial filing by director officer or owner of more than ten percent. 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF
  08/16/13§SC 13D Filing by person(s) reporting owned shares of common stock in a public company >5% Other Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF
  08/14/13         D               Other§Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF
  08/12/13         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF
www.hansenmedical.com/investor-relations/sec-filings.php

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.11.13      1,82      1,90§1,795 1,85 $ 273.038 0,51 M

GrB

Hansen Medical, Inc. (NASDAQ: HNSN)

Corporate Headquarters:
800 E Middlefield Rd.
Mountain View, Calif., 94043
650.404.5800
www.hansenmedical.com

          §European Subsidiary:
Hansen Medical UK Ltd.
30 Eastbourne Terrace
Paddington, London
W2 6LE United Kingdom
+44 207 393 1900

Founded: 2002

IPO: November 2006

Business Objective: Hansen Medical, Inc. (NASDAQ: HNSN) was founded in 2002 to develop products and technology using robotics for the accurate positioning, manipulation and stable control of catheters and catheter-based technologies.

Total Number of Employees as of July 1, 2011: Approximately 175

Products and Intended Use:

   The Magellan™ Robotic System: The Magellan Robotic System and the NorthStar™ Robotic Catheter were created to improve the ability of physicians to efficiently perform endovascular procedures, and to enable new procedures, while exposing the physician to less radiation. The system will enable remote and predictable manipulation of low-profile robotically steerable catheters. The catheters are designed to simplify catheter navigation and therapeutic intervention with minimal learning curve. The Magellan system was CE Marked in the European Union in July 2011 and received FDA clearance in June 2012. The indication for use is to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices.


   The Sensei® X Robotic System: The Sensei X Robotic Catheter System and Artisan® Control Catheter allow physicians to instinctively navigate flexible catheters with great stability and control during interventional procedures. The Sensei X system was cleared by the US FDA and CE Marked in 2009 for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. The Sensei system was cleared by the US FDA and CE Marked in 2007 for use during EP procedures, such as guiding catheters in the treatment of atrial fibrillation.

Media Resource:
Bruce J Barclay, president and CEO
Hansen Medical

The safety and effectiveness of the Sensei® X Robotic Catheter System for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation, have not been established.

The NorthStar™ Robotic Catheter - Not yet CE marked.
Magellan™ Robotic System and NorthStar™ Robotic Catheter - 510(k) Pending.  Not available for sale in the U.S.

Forward-Looking Statements
This fact sheet contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” goal,” “estimate,” and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about, the potential benefits of our Magellan Robotic System on the vascular procedures and the timing and results of commercializing our Magellan Robotic System. Important factors that could cause actual results to differ materially from those indicated by such forwardlooking statements include, among others: engineering, regulatory and sales challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the uncertain timelines, costs and results of pre-clinical and clinical trials; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; the effect of credit, financial and economic conditions on capital spending by our potential customers; our ability to manage expenses and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 filed with the SEC on May 7, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), and Sensei are registered trademarks, and Magellan is a trademark of Hansen Medical, Inc. in the United States and other countries.
Media and Investor Contacts:

Brian Ritchie
212.850.5683
brian.ritchie@fticonsulting.com

John Capodanno
212-850-5705
john.capodanno@fticonsulting.com
www.hansenmedical.com/investor-relations/...tor-fact-sheet.php

Proxy Materials for 2013 Annual Meeting of Stockholders
www.hansenmedical.com/investor-relations/proxy-materials.php

  07/31/13§Hansen Medical Enters Into Agreement With Investors to Receive up to $93 Million in Equity Financing Printer Friendly Version
  07/23/13§Hansen Medical Reports Preliminary Second Quarter 2013 Results Printer Friendly Version
  07/17/13§Marjorie Bowen Appointed to Hansen Medical's Board of Directors Printer Friendly Version
  07/17/13§Hansen Medical and Philips Reinforce Collaboration in Robotic Systems for Endovascular Interventions Printer Friendly Version
  07/10/13§Will Weinstein Appointed to Hansen Medical's Board of Directors Printer Friendly Version
  07/10/13§Hansen Medical to Replace Current Debt Facility With New $33 Million, Interest-Only Debt Facility Through 2017 Printer Friendly Version
  06/26/13§Hansen Medical Announces Initiation of Sell-Side Coverage by Cowen and Company Printer Friendly Version
  06/25/13§Hansen Medical Announces Initiation of Sell-Side Coverage by Wm Smith & Co. Printer Friendly Version
  05/29/13§Hansen Medical Announces U.S. Food and Drug Administration Conditionally Approves New Study Design Evaluating the Use of the Artisan(R) Family of Control Catheters With the Sensei(R) X Robotic System for the Treatment of Atrial Fibrillation Printer Friendly Version
  05/23/13§Hansen Medical to Exhibit Magellan(TM) Robotic System at 2013 Vascular Annual Meeting(R) of the Society for Vascular Surgery Printer Friendly Version
  05/08/13§Hansen Medical Reports First Quarter 2013 Results Printer Friendly Version
  05/08/13§Hansen Medical Announces Agreement in Principle to Settle Securities Class Action Printer Friendly Version
  05/07/13§Hansen Medical's Magellan(TM) Robotic System Scheduled to Be Utilized in Five Live Cases at EuroPCR 2013 Printer Friendly Version
  05/06/13§Hansen Medical to Exhibit Magellan(TM) Robotic System at 8th Annual European Symposium of Vascular Biomaterials in France Printer Friendly Version
  04/30/13§Pre-Clinical Study and Initial Clinical Experience Highlight Potential Benefits of Hansen Medical's Robotic Technology in Treating Carotid Arteries Printer Friendly Version
  04/30/13§Hansen Medical Announces First Quarter 2013 Results Conference Call Printer Friendly Version
  04/29/13§Hansen Medical to Highlight Sensei(R) X Robotic Catheter System and New Artisan Extend(R) Control Catheter at Heart Rhythm Society Annual Meeting Printer Friendly Version
  04/08/13§French National Television Newscast Highlights Endovascular Procedure Featuring Hansen Medical's Magellan(TM) Robotic System Printer Friendly Version
  04/03/13§The Heart and Vascular Center Bad Bevensen Treats First Patients in Germany With Hansen Medical's Magellan(TM) Robotic System Printer Friendly Version
  04/01/13§Hansen Medical to Exhibit Its Magellan(TM) Robotic System at 35th Annual Charing Cross International Symposium Printer Friendly Version
  04/01/13§Hansen Medical Announces the Filing of 30 New U.S. Patent Applications Related to Flexible Medical Robotics Printer Friendly Version
  02/27/13§Hansen Medical Reports Full Year 2012 and Fourth Quarter Results Printer Friendly Version
  02/18/13§Hansen Medical to Present at 33rd Annual Cowen Healthcare Conference Printer Friendly Version
  02/14/13§Hansen Medical Appoints Will Sutton as Chief Operating Officer Responsible for Engineering and Manufacturing Printer Friendly Version
  02/13/13§Hansen Medical Announces Fourth Quarter and Full-Year 2012 Results Conference Call Printer Friendly Version
  01/23/13§Hansen Medical's Magellan(TM) Robotic System Utilized in Two Successful Live Cases at the 25th Annual International Symposium on Endovascular Therapy Printer Friendly Version
  01/16/13§Hansen Medical Names Robert Cathcart Senior Vice President of Global Sales Printer Friendly Version
  01/15/13§Hansen Medical to Exhibit Magellan(TM) Robotic System at 25th Annual International Symposium on Endovascular Therapy
www.hansenmedical.com/investor-relations/releases.php

SK 1,85 $ SKP +0,00 Pott -4,14% ,GrB

   Founded in 2002
   IPO November 2006
   Headquartered in Mountain View, CA

Hansen Medical (NASDAQ: HNSN) the global leader in flexible robotics, was born from the vision of creating a new generation of advanced medical robotics. A generation that would empower and protect physicians while providing enhanced care for patients. The Sensei® Robotic Catheter System and Artisan™ Control Catheter is the first realization of this vision.

We believe the next-generation robotic catheter system, Sensei X, overcomes the limitations of manual technique by facilitating accurate positioning, manipulation, and stable control of catheter and catheter-based technologies during electrophysiology (EP) procedures. The system provides Instinctive Motion™ control and navigation of flexible catheters, resulting in enhanced access, stability, and control in complex interventional procedures. The key is our proprietary Instinctive Motion™ technology that accurately and responsively translates the physician’s hand movements at the motion controller to the robotically controlled steerable catheter in the patient’s anatomy.

This unique combination of technology and ergonomics helps physicians to establish a new standard of care by enabling a new class of percutaneous procedures using advanced electromechanical technology–creating a solution that we believe benefits patients and physicians.
www.hansenmedical.com/investor-relations/corporate-profile.php

Exchange NASDAQ (US Dollar)
     Price§$1.85
Change (%) Stock is Up 0.03 (1.65%)
    Volume§273,038
Today's Open $1.82
Previous Close $1.82
Intraday High $1.90
Intraday Low $1.80
52 Week High $2.75
52 Week Low $1.14
Data as of 11/15/13 4:00 p.m. ET
www.hansenmedical.com/investor-relations/stock-quote.php

Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread Zeit

Frankfurt 4.600 1,32 € 1,346 € 4.500 1,97% 11:19:00

Nasdaq 300 1,76 $ 2,21 $ 500 25,57% 10:00:01

Kosmonova buran und MfG und Dreimal Rosamunde